Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Breast Neoplasms
/ genetics
Cell Line, Tumor
Female
Fibroblasts
/ cytology
Humans
Lapatinib
/ pharmacology
Phosphatidylinositol 3-Kinases
/ genetics
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins c-akt
/ genetics
Receptor, ErbB-2
/ antagonists & inhibitors
Signal Transduction
/ drug effects
TOR Serine-Threonine Kinases
/ genetics
breast cancer
cell–cell interactions
drug resistance
fibroblasts
tumor microenvironment
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
14 07 2020
14 07 2020
Historique:
pubmed:
1
7
2020
medline:
22
9
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
Despite the implementation of multiple HER2-targeted therapies, patients with advanced HER2
Identifiants
pubmed: 32601199
pii: 2000648117
doi: 10.1073/pnas.2000648117
pmc: PMC7368275
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Lapatinib
0VUA21238F
MTOR protein, human
EC 2.7.1.1
Receptor, ErbB-2
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
16500-16508Subventions
Organisme : NCI NIH HHS
ID : R00 CA222554
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217842
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA168504
Pays : United States
Informations de copyright
Copyright © 2020 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
Competing interest statement: D.A.D. is on the Academic Advisory Board of Oncology, Analytics, Inc, and consults for Novartis. G.B.M. receives support or acts as consultant for AstraZeneca, ImmunoMET, Ionis, Lilly, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, and Tarveda. J.S.B. consults for Agios and Effector Pharmaceuticals.
Références
Biochem Pharmacol. 2019 Apr;162:250-261
pubmed: 30668936
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
pubmed: 17440164
Nat Commun. 2016 Jul 12;7:12156
pubmed: 27402251
Clin Cancer Res. 2012 May 1;18(9):2603-12
pubmed: 22407832
Anticancer Agents Med Chem. 2012 Feb;12(2):151-62
pubmed: 22043997
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
Nature. 2007 Jan 25;445(7126):437-41
pubmed: 17206155
Mol Cancer Ther. 2010 Jun;9(6):1489-502
pubmed: 20501798
Cell Syst. 2018 Mar 28;6(3):329-342.e6
pubmed: 29550255
Clin Cancer Res. 2017 Sep 1;23(17):5123-5134
pubmed: 28487443
Sci Transl Med. 2017 Aug 2;9(401):
pubmed: 28768804
J Clin Oncol. 2016 Jun 20;34(18):2115-24
pubmed: 27091708
Cancer Cell. 2016 Mar 14;29(3):255-269
pubmed: 26977878
Cancer Res. 2016 Nov 15;76(22):6495-6506
pubmed: 27671678
Cancer Metastasis Rev. 2018 Dec;37(4):577-597
pubmed: 30465162
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6
pubmed: 21321214
Biomed Res Int. 2018 Jun 5;2018:6075403
pubmed: 29967776
Nature. 2012 Jul 26;487(7408):500-4
pubmed: 22763439
Nat Commun. 2015 Sep 24;6:8390
pubmed: 26399630
NPJ Breast Cancer. 2017 May 1;3:18
pubmed: 28649658
Nat Rev Clin Oncol. 2017 Nov;14(11):669-681
pubmed: 28762384
Ann Oncol. 2016 Oct;27(10):1867-73
pubmed: 27484801
Crit Rev Oncol Hematol. 2019 Jul;139:53-66
pubmed: 31112882
Nat Methods. 2016 Jun;13(6):521-7
pubmed: 27135972
Nat Commun. 2017 Aug 28;8(1):365
pubmed: 28848242
Clin Cancer Res. 2009 Dec 1;15(23):7266-76
pubmed: 19934303
Ther Adv Med Oncol. 2019 Mar 19;11:1758835919833519
pubmed: 30911337
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48
pubmed: 31548601
Cell. 2018 Feb 8;172(4):841-856.e16
pubmed: 29395328
Clin Cancer Res. 2018 Jan 15;24(2):395-406
pubmed: 29079660
Breast Cancer Res Treat. 2015 Feb;150(1):157-67
pubmed: 25687356
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3787-92
pubmed: 17360431
Mol Cancer Ther. 2007 Aug;6(8):2188-97
pubmed: 17699716
Ann Pharmacother. 2019 Jun;53(6):612-620
pubmed: 30607980
Nature. 2017 Nov 9;551(7679):247-250
pubmed: 29088702
Clin Cancer Res. 2014 Jul 1;20(13):3507-20
pubmed: 24879796
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5569-74
pubmed: 17376864
Cell Cycle. 2011 Aug 1;10(15):2521-8
pubmed: 21768775
Oncotarget. 2015 Dec 1;6(38):41123-33
pubmed: 26516700
Breast Cancer Res. 2011;13(6):227
pubmed: 22078026
Cancer Biol Ther. 2015;16(3):402-11
pubmed: 25692408
Mol Cancer Ther. 2011 Mar;10(3):395-403
pubmed: 21216931
Cell Signal. 2016 Aug;28(8):907-16
pubmed: 27094713
Cancer Res. 2017 Apr 15;77(8):1842-1853
pubmed: 28209619
Mol Syst Biol. 2018 Aug 6;14(8):e8322
pubmed: 30082272
Nat Commun. 2014 May 29;5:3887
pubmed: 24871328
Clin Cancer Res. 2012 Dec 15;18(24):6784-91
pubmed: 23092874
Nature. 2012 Jul 26;487(7408):505-9
pubmed: 22763448
Clin Cancer Res. 2017 Apr 1;23(7):1710-1721
pubmed: 27702820
Cell. 2016 May 19;165(5):1092-1105
pubmed: 27133165
Breast Cancer Res Treat. 2011 Aug;128(3):599-606
pubmed: 20945086
Nat Med. 2016 Jul;22(7):723-6
pubmed: 27270588
Eur J Immunol. 2013 Oct;43(10):2718-29
pubmed: 23843024
Lancet Oncol. 2016 Mar;17(3):357-366
pubmed: 26822398
Lancet Oncol. 2014 May;15(6):580-91
pubmed: 24742739
Breast Cancer Res Treat. 2018 Feb;167(3):731-740
pubmed: 29110152
Breast Cancer Res. 2014 Jan 23;16(1):R9
pubmed: 24451154